Robert Wanerman, Senior Counsel in the Health Care and Life Sciences Practice in the Washington, DC office, was quoted in an article about the proliferation of interest in Israeli biotech companies.
The article, “The Bio-Affair with an Israeli and American Flair,” reported that an estimated 6,000 people from around the world arrived in Tel Aviv for the eighth annual, three-day biotech conference ILSI BioMed Israel 2009. Epstein Becker Green has represented about three dozen Israeli companies over the last five years.
Wanerman said the Firm has targeted companies that are maturing: “We try to get them to think about [regulatory] issues early on,” he added.
In Israel, Wanerman said, many smaller companies are able to get “up and running” with a fraction of the capital needed in the United States: “If you can get something faster, more efficient, and has a better outcome, it doesn’t matter where you’re from.”
This year, he noted, there were more attendees at the conference, and more early-stage companies coming to learn about the market.
The article appeared on the Web site of ISRAEL21c, a non-profit educational foundation with a mission to focus media and public attention on the 21st century Israel.